KR930003915A - 장기 이식에 있어서의 거부 반응 치료 약제 - Google Patents

장기 이식에 있어서의 거부 반응 치료 약제 Download PDF

Info

Publication number
KR930003915A
KR930003915A KR1019920014957A KR920014957A KR930003915A KR 930003915 A KR930003915 A KR 930003915A KR 1019920014957 A KR1019920014957 A KR 1019920014957A KR 920014957 A KR920014957 A KR 920014957A KR 930003915 A KR930003915 A KR 930003915A
Authority
KR
South Korea
Prior art keywords
medicament
use according
rejection
treatment
physiologically acceptable
Prior art date
Application number
KR1019920014957A
Other languages
English (en)
Other versions
KR100253450B1 (ko
Inventor
라이더 바르트레트 로버트
Original Assignee
마이어, 라피체
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이어, 라피체, 훽스트 아크티엔게젤샤프트 filed Critical 마이어, 라피체
Publication of KR930003915A publication Critical patent/KR930003915A/ko
Application granted granted Critical
Publication of KR100253450B1 publication Critical patent/KR100253450B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Abstract

내용 없음.

Description

장기 이식에 있어서의 거부 반응 치료 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 이식된 장기에 대한 장기 수용자의 거부 반응을 치료하기 위한 약제의 제조를 위한 일반식(1) 및/또는 (2)의 화합물(여기서, 일반식(2)의 화합물은 본래 형태 또는 생리학적으로 허용되는 염 형태로 존재한다)의 용도.
  2. 제1항에 있어서, 약제를 이식 전, 이식하는 동안 및/또는 이식 후에 장기 수용자 또는 공급자에게 투여함을 특징으로 하는 용도.
  3. 제1항 또는 제2항에 있어서, 약제를 초급성 또는 급성 거부 반응의 치료에 사용함을 특징으로 하는 용도.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 약제를 만성 거부 반응의 치료에 사용함을 특징으로 하는 용도.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 약제를 한종에서 다른 종으로 장기를 이식하는데 사용함을 특징으로 하는 용도.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 동종친화성 항체 또는 이종친화성 항체의 양을 감소시킴을 특징으로 하는 용도.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 약제를 포유동물, 특히 사람에게 사용함을 특징으로 하는 용도.
  8. 제1항 내지 제7항중 어느 한 항에 있어서, 요산병, 치료제, 혈소판 응집 억제제, 진통제 및 스테로이드성 또는 비스테로이드성 소염제와 같은 다른 활성 물질을 사용함을 특징으로 하는 용도.
  9. 유효량의 화합물(1) 및/또는 (2) (여기서, 화합물(2)는 본래 형태 또는 생리학적으로 허용되는 염의 형태로 존재할수 있다)을 포함하는, 이식된 장기에 대한 장기 수용자의 거부 반응을 치료하기 위한 약제.
  10. 화합물(1) 및/또는 (2)의 생리학적으로 허용되는 염을 생리학적으로 허용되는 부형제 및 다른 적합한 활성물질, 첨가제 또는 보조제를 사용하여 적합한 투여 형태 화함을 포함하여, 이식된 장기에 대한 장기 수용자의 거부 반응을 치료하기 위한 제9항에서 청구된 약제를 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920014957A 1991-08-22 1992-08-20 장기 이식에 있어서의 거부 반응 치료용 약제학적 조성물 KR100253450B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4127737.6 1991-08-22
DE4127737A DE4127737A1 (de) 1991-08-22 1991-08-22 Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen

Publications (2)

Publication Number Publication Date
KR930003915A true KR930003915A (ko) 1993-03-22
KR100253450B1 KR100253450B1 (ko) 2000-07-01

Family

ID=6438804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920014957A KR100253450B1 (ko) 1991-08-22 1992-08-20 장기 이식에 있어서의 거부 반응 치료용 약제학적 조성물

Country Status (18)

Country Link
US (3) US5728721A (ko)
EP (1) EP0529500B1 (ko)
JP (1) JP3285226B2 (ko)
KR (1) KR100253450B1 (ko)
AT (1) ATE113835T1 (ko)
AU (1) AU654031B2 (ko)
CA (1) CA2076555C (ko)
CZ (1) CZ281353B6 (ko)
DE (2) DE4127737A1 (ko)
DK (1) DK0529500T3 (ko)
ES (1) ES2065738T3 (ko)
HU (1) HU219402B (ko)
IL (1) IL102886A (ko)
MX (1) MX9204875A (ko)
RU (1) RU2067862C1 (ko)
SK (1) SK279323B6 (ko)
TW (1) TW210284B (ko)
ZA (1) ZA926310B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5814649A (en) * 1994-10-17 1998-09-29 Hoechst Pharmaceuticals & Chemicals K.K. Preventive and remedy for type 1 allergic diseases
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19857009A1 (de) * 1998-12-10 2000-06-15 Aventis Pharma Gmbh Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
IL161522A0 (en) * 2001-10-25 2004-09-27 Atherogenics Inc Compounds and methods for treating transplant rejection
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2005011669A1 (ja) * 2003-08-05 2006-09-14 大日本住友製薬株式会社 経皮投与用医薬組成物
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436263C2 (de) 1974-07-27 1983-02-17 Hoechst Ag, 6000 Frankfurt Thiazolidinderivate und Verfahren zu ihrer Herstellung
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8320969D0 (en) * 1983-08-03 1983-09-07 Ici Plc Transparent sheet
DE3405727A1 (de) 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE4101324A1 (de) 1991-01-18 1992-07-23 Hoechst Ag Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
ATE128353T1 (de) 1991-10-23 1995-10-15 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonsäureamidderiva e und deren verwendung als arzneimittel mit immunmodulatorischer eigenschaft.
US5624946A (en) 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US6223209B1 (en) * 1997-09-30 2001-04-24 Ncr Corporation Distributed world wide web servers

Also Published As

Publication number Publication date
AU654031B2 (en) 1994-10-20
IL102886A0 (en) 1993-01-31
US5728721A (en) 1998-03-17
EP0529500A1 (de) 1993-03-03
DE59200773D1 (de) 1994-12-15
SK258292A3 (en) 1995-09-13
JP3285226B2 (ja) 2002-05-27
TW210284B (ko) 1993-08-01
CZ281353B6 (cs) 1996-09-11
SK279323B6 (sk) 1998-10-07
US7402601B2 (en) 2008-07-22
DK0529500T3 (da) 1995-04-18
CA2076555A1 (en) 1993-02-23
EP0529500B1 (de) 1994-11-09
HUT64845A (en) 1994-03-28
JPH05208909A (ja) 1993-08-20
CA2076555C (en) 2003-07-29
KR100253450B1 (ko) 2000-07-01
CZ258292A3 (en) 1993-03-17
AU2124792A (en) 1993-02-25
US20050080118A1 (en) 2005-04-14
DE4127737A1 (de) 1993-02-25
HU219402B (hu) 2001-04-28
RU2067862C1 (ru) 1996-10-20
IL102886A (en) 1996-01-19
MX9204875A (es) 1993-02-01
US6288098B1 (en) 2001-09-11
ATE113835T1 (de) 1994-11-15
ES2065738T3 (es) 1995-02-16
ZA926310B (en) 1993-04-28

Similar Documents

Publication Publication Date Title
KR930003915A (ko) 장기 이식에 있어서의 거부 반응 치료 약제
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
ES2714550T3 (es) Composiciones farmacéuticas y método para tratar la inflamación en ganado bovino y otros animales
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
KR920021140A (ko) 약학 조성물
RU2002115406A (ru) Соединение, обладающее свойствами высвобождения гормона роста
AU760791C (en) Anthelmintic composition
US5550153A (en) Method for treating heartworm-infected canines
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
PETROVIC et al. Promotion of bone calcification by sodium fluoride: short-term experiments on newborn rats using tetracycline labeling
KR960003729A (ko) 항과혈당증 작용을 지닌 약제
McIver Increased susceptibility to chloroform poisoning produced in the albino rat by injection of crystalline thyroxin
RU2209064C2 (ru) Новое применение в медицинских целях
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
KR900701278A (ko) 바이러스 감염 치료용 담즙산
JP2831030B2 (ja) ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
KR880004810A (ko) 소화성 궤양 치료제
US3026247A (en) Pharmaceutical preparation
Greendyke et al. Chronic histoplasmosis: Report of a patient successfully treated with amphotericin B

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120109

Year of fee payment: 13

EXPY Expiration of term